Amylyx Pharmaceuticals, Inc.
AMLX
Rangering i aksjer
#4525
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Aksjekurs
$26.87
Markedsverdi
$3.37B
Endring (1 dag)
2.01%
Endring (1 år)
79.73%
Land
US
Handel Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
Utbyttehistorikk for Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (aksjesymbol: AMLX) har gitt totalt 3 utbyttebetalinger.
Summen av alle utbytter (justert for aksjesplitt): $1.02
Utbytteavkastning (TTM): 0
Summen av alle utbytter (justert for aksjesplitt): $1.02
Utbytteavkastning (TTM): 0
Utbyttebetalinger for Amylyx Pharmaceuticals, Inc. (AMLX) fra 2017 til 2026
Årlige utbyttebetalinger
| År | Utbytte (justert for aksjesplitt) | Endre |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
Liste over alle utbyttebetalinger
| År | Utbytte | Endre |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
Utbyttebetalinger for lignende selskaper eller konkurrenter
| Selskap | Antall utbyttebetalinger | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
